Newcells Biotech

Newcells Biotech operates as a specialized service and product provider in the preclinical drug discovery space, leveraging advanced in vitro organoid and tissue models. Its core expertise lies in building complex, human cell-based models of the retina, kidney, and lung that mimic in vivo physiology for applications in toxicology, disease modeling, and gene therapy assessment. The company collaborates with biopharma clients to run bespoke studies or supply models, aiming to enhance predictive power and support the 3Rs (Replacement, Reduction, Refinement) in research. Based in Newcastle upon Tyne, it is a private, revenue-generating entity focused on bridging the gap between in vitro data and clinical outcomes.

Proprietary suite of functional in vitro tissue models (organoids and complex co-cultures) derived from primary cells and iPSCs, focusing on retina, kidney (proximal tubule), and lung airway physiology for predictive drug discovery assays.

Newcells competes in the niche of complex in vitro models against other specialized CROs and academic service providers, as well as larger organ-on-a-chip companies like Emulate and Mimetas. It also faces indirect competition from traditional toxicology CROs and in-house pharma capabilities. Its differentiation lies in its deep tissue-specific physiological expertise in retina, kidney, and lung models.